Glyburide, also known as glibenclamide, is a sulfonylurea medication used to treat type 2 diabetes. Its synthesis involves several chemical steps, and intellectual property surrounding these processes, including the use of cyclohexyl isocyanate, has been subject to patents.
What is the role of cyclohexyl isocyanate in glyburide synthesis?
Cyclohexyl isocyanate is a key reagent in the synthesis of glyburide. It reacts with an amine group to form a urea linkage, which is a structural component of the glyburide molecule [1]. Specifically, it is used to introduce the cyclohexylsulfonylurea moiety.
Are there patents covering glyburide synthesis using cyclohexyl isocyanate?
Yes, patents have historically covered various aspects of glyburide synthesis, including specific chemical routes and intermediates. Some of these patents may have disclosed or claimed methods utilizing cyclohexyl isocyanate [2]. The scope of these patents would determine their applicability and whether they are still in force.
When do patents related to glyburide synthesis expire?
The expiration of patents for glyburide synthesis would depend on the specific patent's filing date, grant date, and any patent term extensions it may have received. Original patents for glyburide itself have long since expired, but patents covering novel synthetic routes or improvements could have later expiration dates [3]. Information on specific patent expiration dates would require a detailed search of patent databases.
Can generic manufacturers use patented synthesis methods for glyburide?
Generic manufacturers can typically only use patented synthesis methods after the relevant patents have expired. If a patent covers a specific, non-obvious synthetic route that a generic company wishes to use, they must wait for patent protection to lapse. Alternatively, they may develop alternative, non-infringing synthetic pathways [4].
What are the challenges in patenting pharmaceutical synthesis routes?
Patenting pharmaceutical synthesis routes requires demonstrating novelty, inventiveness, and industrial applicability. Companies often seek patents for more efficient, cost-effective, or environmentally friendly methods, or for routes that yield a purer product. However, these patents can be challenged by competitors who argue that the claimed synthesis is obvious, not novel, or already known [5].
Who are the major manufacturers of glyburide?
Major manufacturers of glyburide include pharmaceutical companies that produce both the branded and generic versions of the drug. Companies like Pfizer (which originally marketed DiaBeta) and various generic drug manufacturers globally produce glyburide for the market [6].
What is the difference between glyburide and other sulfonylureas?
Glyburide is a second-generation sulfonylurea. While all sulfonylureas work by stimulating the pancreas to release more insulin and decreasing glucose production by the liver, they differ in their potency, duration of action, and metabolic profiles. Glyburide is generally considered one of the more potent and longer-acting sulfonylureas [7].
Sources:
1. https://pubchem.ncbi.nlm.nih.gov/compound/Glyburide
2. https://patents.google.com/ (General search for "glyburide synthesis patent" and "cyclohexyl isocyanate patent")
3. https://www.uspto.gov/learning-and-resources/glossary-terms/patent-term-extension
4. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andanas-for-generic-drugs/generic-drugs-process
5. https://www.uspto.gov/patents/basics/what-patent
6. https://www.drugs.com/drug-manufacturers.html?drug_name=Glyburide
7. https://www.mayoclinic.org/drugs-supplements/glyburide-oral-route/description/drg-20069461